Peptidyl Arginine Deiminase 4 (PAD4, also PADI4) is a Calcium-dependent enzyme that catalyzes the post-translational conversion of positively-charged Arginine residues to neutral Citrulline (Citrullination) in nuclear and cytoplasmic proteins. This post-translational modification is essential for neutrophil extracellular trap (NETosis) formation via chromatin decondensation and is centrally implicated in autoimmune diseases, particularly rheumatoid arthritis, through generation of citrullinated autoantigens.
Imagine DNA normally wrapped around histone proteins like thread wound tightly around 8 spools (the histone octamer), kept compact by electrostatic attraction—the positively-charged arginine residues on histones grip the negatively-charged DNA backbone. PAD4 is the scissors that snips off the positive charges. When a neutrophil gets the distress signal (high Calcium), PAD4 floods the nucleus and starts converting arginines to citrullines—neutral amino acids that can't hold the DNA tight anymore. The chromatin unspools like a ball of yarn dropped down stairs, expanding to fill the entire cell and eventually bursting out as a sticky web (a NET) to trap bacteria. This is lifesaving in acute infection—the NET is a physical trap coated with antimicrobial proteins. But PAD4 doesn't stop at histones. It also citrullinates structural proteins like vimentin and fibrinogen in joints and connective tissue, creating "remodelled" proteins the immune system has never seen before. In rheumatoid arthritis, the immune system sees these citrullinated proteins as foreign invaders and mounts an antibody attack (anti-CCP antibodies) against the body's own tissues. PAD4 is the molecular editor that changes "self" into "non-self" by changing one amino acid at a time.
PAD4 activation and function proceeds through the following cascade:
Activation Pathway:
- neutrophil activation (via PAMPs, DAMPs, or cytokines like IL-8, TNF-α)
- Intracellular Calcium influx (via store-operated calcium entry, receptor-operated channels)
- Ca²⁺ binds to PAD4 (5 calcium-binding sites; Kd ~1-10 μM; requires 200-500 μM Ca²⁺ for maximal activity)
- Conformational change exposes active site (Cys645 nucleophile)
- PAD4 translocates to nucleus (nuclear localization signal-dependent)
Enzymatic Reaction:
- Protein-Arginine + H₂O → Protein-Citrulline + NH₃
- Deimination (hydrolytic deamination) removes the positively-charged imine group
- Net loss of +1 charge per arginine converted
Primary Substrates in NETosis:
- Histone H3 (Arg2, Arg8, Arg17, Arg26) — critical for chromatin decondensation
- Histone H4 (Arg3) — synergistic with H3 citrullination
- Histone H2A — contributes to decondensation
- Nuclear envelope proteins (lamin B1) — facilitates envelope breakdown
Chromatin Decondensation Mechanism:
- Citrullination of H3/H4 reduces positive charge
- Electrostatic repulsion between DNA (negative) and histones (now less positive) weakens
- Chromatin swelling (euchromatin → decondensed chromatin)
- neutrophil elastase and myeloperoxidase translocate to nucleus (synergistic with PAD4)
- Nuclear envelope breakdown
- Plasma membrane rupture → NET extrusion
Citrullination in Autoimmunity:
PAD4 also citrullinates extracellular and intracellular proteins in inflamed tissues:
- Fibrinogen (citrullinated fibrinogen is a major RA autoantigen)
- Vimentin (intermediate filament protein; citrullinated vimentin = mutated citrullinated vimentin, Sa antigen)
- Collagen type II (in cartilage)
- α-enolase (glycolytic enzyme)
These neo-epitopes are recognized by ACPA (anti-citrullinated protein antibodies), the diagnostic hallmark of rheumatoid arthritis.
graph TD
A[Neutrophil Activation] --> B["Ca²⁺ Influx 200-500 μM"]
B --> C[PAD4 Activation]
C --> D[Nuclear Translocation]
D --> E[Histone Citrullination]
E --> F[Chromatin Decondensation]
F --> G[NET Formation]
C --> H[Extracellular Protein Citrullination]
H --> I[Fibrinogen, Vimentin, Collagen II]
I --> J[Neo-epitope Formation]
J --> K[ACPA Production]
K --> L[Autoimmune Attack]
G --> M{Context-Dependent Outcome}
M -->|Acute Infection| N[Pathogen Trapping - Resolution]
M -->|Chronic Inflammation| O[Tissue Damage - Impaired Resolution]
style C fill:#ff9999
style K fill:#ffcc99
style M fill:#ccffcc
Regulation:
- Inhibitors: Chloramidine, Cl-amidine (irreversible), BB-Cl-amidine (cell-permeable), GSK484 (reversible)
- Endogenous regulation: Limited; primarily controlled by Ca²⁺ availability
- Oxidative inactivation: Excessive ROS can inactivate PAD4 (Cys645 oxidation)
- Transcriptional control: Upregulated by TNF-α, IFN-γ, hypoxia (HIF-1α)
PAD4 is a double-edged sword in clinical practice—essential for innate immunity yet pathogenic in chronic inflammation and autoimmunity.
Relevance to Metamodels:
- Selfish Immune System: PAD4-driven NETosis prioritizes pathogen neutralization over tissue preservation. NETs are highly inflammatory and impair resolution if not cleared efficiently. The immune system "chooses" to sacrifice neutrophils and surrounding tissue to contain infection.
- Evolutionary Mismatch: PAD4 evolved for acute infections (hours to days). In chronic inflammatory states (obesity, smoking, periodontitis, chronic stress), sustained PAD4 activation generates persistent citrullinated antigens, driving autoimmunity. The system wasn't designed for decades of low-grade inflammation.
- Resolution Dysfunction: Excessive NETosis consumes resolution machinery. NETs contain myeloperoxidase, neutrophil elastase, and histones—all cytotoxic. If efferocytosis of NETs is impaired, DAMPs accumulate and perpetuate inflammation.
Clinical Conditions:
- Rheumatoid Arthritis: ACPA-positive RA patients have elevated PAD4 activity in synovial fluid (citrullination of fibrinogen, vimentin). Anti-CCP antibodies (>20 U/mL diagnostic; >60 U/mL high specificity) predict erosive disease. PAD4 single nucleotide polymorphisms (PADI4 haplotype) confer 2-3× increased RA risk in Asian populations.
- Lupus (SLE): Impaired NET clearance (anti-NET antibodies, DNase deficiency) leads to NETosis-driven vascular damage and lupus nephritis.
- Periodontitis: Porphyromonas gingivalis produces its own PAD (PPAD), which citrullinates gingival proteins and bacterial antigens, potentially triggering RA in genetically susceptible hosts (the "periodontal hypothesis" of RA).
- COVID-19/ARDS: Excessive NETosis (driven by PAD4) causes pulmonary microthrombosis and endothelial damage. Plasma NET markers (cell-free DNA, MPO-DNA complexes) correlate with severity.
- Wound Healing: NETs form a scaffold for healing in the inflammatory phase, but persistent NETs in diabetic ulcers or chronic wounds impair re-epithelialization (NETs degrade growth factors like VEGF).
Intervention Implications:
- PAD4 Inhibitors: Under investigation for RA, lupus, ARDS. Risk: impaired antimicrobial defense. Requires careful patient selection (rule out active infection).
- Omega-3 SPMs: Resolvins, Maresins, and Protectins inhibit excessive NETosis and promote NET clearance via enhanced efferocytosis. RvD1 downregulates PAD4 expression in neutrophils.
- Lifestyle: Smoking cessation (smoking increases PAD4 activity and ACPA risk 20-40×). Oral hygiene (reduce P. gingivalis burden). Intermittent fasting (reduces neutrophil priming and lowers basal PAD4).
- Monitoring: In RA, track anti-CCP titres and CRP. Rising anti-CCP despite DMARD therapy may indicate ongoing PAD4-driven citrullination (consider biologics targeting IL-6, TNF-α).
Thresholds:
- Anti-CCP antibodies >20 U/mL = diagnostic for RA
- NET markers (MPO-DNA >10 ng/mL) associated with thrombotic risk
- PADI4 haplotype (SNPs rs2240340, rs1748033) increases RA risk
- Calcium-dependent: Requires 200-500 μM intracellular Ca²⁺ for activation (resting neutrophils ~100 nM)
- Five isoforms: PAD1, PAD2, PAD3, PAD4, PAD6; only PAD4 has nuclear localization signal
- Primary sites: Expressed in neutrophils, macrophages, mast cells, eosinophils; low levels in monocytes
- Histone targets: H3 (Arg2, 8, 17, 26), H4 (Arg3), H2A — citrullination reduces DNA-histone binding by ~60%
- RA autoantigens: Citrullinated fibrinogen, vimentin (Sa antigen), α-enolase, collagen type II
- Genetic risk: PADI4 haplotype increases RA risk 1.5-3× in Asian populations; weaker association in Europeans
- NETosis kinetics: PAD4 activation within 30-60 minutes of neutrophil stimulation; NET release at 2-4 hours
- Inhibitors: Cl-amidine (IC₅₀ ~5 μM), GSK484 (IC₅₀ ~50 nM, reversible)
- Synergy with enzymes: Works with neutrophil elastase and myeloperoxidase for full chromatin decondensation
- Resolution deficit: NETs persist 24-72 hours if macrophage efferocytosis is impaired
- NETosis — PAD4 is the rate-limiting enzyme for chromatin decondensation and NET extrusion
- neutrophil — exclusively expressed in granulocytes where it mediates antimicrobial responses and autoimmunity
- Citrullination — PAD4 catalyzes the deimination reaction that defines citrullination
- Calcium — absolutely dependent on Ca²⁺ influx for conformational activation; 5 Ca²⁺ binding sites
- rheumatoid arthritis — PAD4-generated citrullinated proteins are the target of ACPA antibodies
- ACPA — anti-citrullinated protein antibodies recognize PAD4-modified fibrinogen, vimentin, collagen
- Citrullinated proteins — fibrinogen, vimentin, α-enolase, collagen II, histones H3/H4
- wound healing — NETs provide early scaffold but impair resolution if not cleared; PAD4 inhibition accelerates diabetic wound closure
- autoimmunity — excessive PAD4 activity generates neo-epitopes driving adaptive immune responses
- DAMPs — citrullinated histones and extruded chromatin act as damage signals perpetuating inflammation
- resolution — unresolved NETs consume SPMs and phagocytic capacity; PAD4 inhibition or NET clearance restores resolution
- Arginine — substrate for PAD4; supplementation may compete but risks fueling NETosis
- IL-8 — potent neutrophil chemoattractant that primes PAD4 activation
- TNF-α — upregulates PAD4 gene expression and primes neutrophils for NETosis
- myeloperoxidase — synergizes with PAD4 in chromatin decondensation; co-released in NETs
- Histones — PAD4 citrullinates H3, H4, H2A causing charge loss and chromatin expansion
- Inflammation — chronic inflammation sustains PAD4 activity leading to autoantigen generation
- Chronic inflammation — persistent PAD4-driven citrullination creates autoimmune risk in RA, lupus, periodontitis
- Porphyromonas gingivalis — produces bacterial PAD (PPAD) that citrullinates host proteins, triggering RA in susceptible individuals
- Resolvins — RvD1, RvE1 inhibit PAD4 expression and excessive NETosis while preserving antimicrobial function
- Efferocytosis — macrophage clearance of NETs is essential to prevent PAD4-driven autoinflammation
- COVID-19 — excessive PAD4-driven NETosis causes pulmonary microthrombosis and ARDS
- Smoking — increases PAD4 activity in lungs and joints; 20-40× increased ACPA-positive RA risk in smokers
- Omega-3 fatty acids — DHA and EPA reduce neutrophil priming and PAD4 activity; substrates for SPM synthesis
- Periodontitis — oral dysbiosis and P. gingivalis PPAD activity drive systemic citrullination and RA risk